Pharmacology of mycophenolate mofetil: Recent insights and clinical consequences;Pharmacologie du myocoph́enolate mofétil: Données récentes et conséquences cliniques

Nephrologie

Volumn 22, Issue 7, 2001, Pages 331-337

  Thervet, E ^a   Anglicheau, D ^a   Legendre, C ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Immunosuppression; Kidney transplantation; Mycophenolate mofetil; Pharmacology

Indexed keywords

GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A8; INOSINATE DEHYDROGENASE; ISOPROTEIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; UNCLASSIFIED DRUG; DRUG DERIVATIVE; ENZYME INHIBITOR; IMMUNOSUPPRESSIVE AGENT; ISOENZYME; MYCOPHENOLIC ACID; NUCLEIC ACID;

AREA UNDER THE CURVE; CLINICAL PRACTICE; CLINICAL TRIAL; DIALYSIS; DRUG EFFICACY; DRUG GLUCURONIDATION; DRUG MECHANISM; DRUG METABOLISM; DRUG USE; ENZYME BINDING; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INDIVIDUALITY; KIDNEY TRANSPLANTATION; REVIEW; SIDE EFFECT; ANIMAL; BIOAVAILABILITY; BIOSYNTHESIS; BIOTRANSFORMATION; CATTLE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; CHRONIC KIDNEY FAILURE; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; DRUG INTERACTION; DRUG SCREENING; GRAFT VERSUS HOST REACTION; KIDNEY; METABOLISM; MULTICENTER STUDY; RABBIT; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY;

ANIMALS; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CATTLE; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; ENZYME INHIBITORS; GLUCURONOSYLTRANSFERASE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; ISOENZYMES; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MULTICENTER STUDIES; MYCOPHENOLIC ACID; NUCLEIC ACIDS; RABBITS; RANDOMIZED CONTROLLED TRIALS; RENAL DIALYSIS;

EID: 0034740274     PISSN: 02504960     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate
2. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection
3. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate mofetil investigators
4. Perspectives des nouveaux immunosuppresseurs en greffe de moelle et pour le traitement des maladies autoimmunes
5. Mycophenolic acid binding to human serum albumin: Characterization and relationship to pharmacodynamics
6. High-performance liquid chromatographic method for the determination of mycophenolate mofetil in human plasma
7. Manual and automated (robotic) high-performance liquid chromatograhy methods for the determination of mycophenolic acid and its glucuronide conjugate in human plasma
8. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after singe-dose oral and intravenous administration
9. Determination of a new immunosuppressant, mycophenolate mofetil, and its active metabolite, mycophenolic acid, in rat and human body fluids by high-performance liquid chromatography
10. Simple and sensitive high-performance liquid chromatographic method for the determination of mycophenolic acid in plasma
11. Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil
12. Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and EMIT
13. EMIT mycophenolic acid assay: Manufacturer's guidelines
14. Evaluation of an immunoassay (EMIT) for mycophenolic acid in plasma from renal transplant recipients compared with a high-performance liquid chromatography assay
15. Induction of cytokine release by the acyl glucuronide of mycophenolic acid: A link to side effects?
16. Clinical pharmacokinetics of mycophenolate mofetil
17. Identification of uridine diphosphate glucuronosyltransferases involved in the metabolism and clearance of mycophenolic acid
18. Human colorectal carcinoma cells in vitro as a means to assess the metabolism of analogs of mycophenolic acid
19. Enterohepatic circulation model for population pharmacokinetic analysis
20. Pharmacokinetics of mycophenolic acid in renal insufficiency
21. Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure
22. RS61443 - A phase I clinical trial and pilot rescue study
23. The effect of renal insufficiency on mycophenolic acid protein binding
24. Trough blood concentrations in long-term treatment with mycophenolate mofetil
25. Mycophenolate mofetil as maintenance immunosuppression in pediatric renal transplantation
26. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: Implications for therapeutic drug monitoring
27. Pharmacokinetics, and tolerance of mycophenolate mofetil in renal transplant children
28. Intravenous mycophenolate mofetil: Safety, tolerability and pharmacokinetics
29. The monitoring of immunosuppressive drugs: A pharmacodynamic approach
30. IMP dehydrogenase, an enzyme linked with proliferation and malignancy
31. Two distinct cDNAs for human IMP dehydrogenase
32. Characterization of human type I and type II IMP dehydrogenases
33. Inosine-5′-monophosphate dehydrogenase: Regulation of expression and role in cellular proliferation and T lymphocyte activation
34. Crystal structure of human type II inosine monophosphate dehydrogenase: Implications for ligand binding and drug design
35. IMP dehydrogenase: Mechanism of action and inhibition
36. The structure of inosine 5′-monophosphate dehydrogenase and the design of novel inhibitors
37. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression by measuring IMP dehydrogenase activity
38. Development and application of a high-performance liquid chromatography-based assay for determination of the activity of inosine 5′-monophosphate dehydrogenase in whole blood and isolated mononuclear cells
39. Pharmacodynamic monitoring of mycophenolic acid in rabbit heterotopic heart transplant model
40. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression by measurement of inosine monophosphate dehydrogenase activity in a canine model
41. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients
42. Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil
43. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation
44. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression
45. Effect of cyclosporin on mycophenolic acid trough levels in kidney transplant recipients
46. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings
47. Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients
48. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation
49. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients FK506/MMF Dose-Ranging Kidney Transplant Study Group
50. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients